Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study (PRIISM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00810095
Recruitment Status : Completed
First Posted : December 17, 2008
Results First Posted : July 26, 2012
Last Update Posted : July 26, 2012
Sponsor:
Information provided by (Responsible Party):
MindFrame, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary study objective is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients experiencing an ischemic stroke.

Condition or disease Intervention/treatment Phase
Ischemic Stroke Device: MindFrame System Phase 2

Detailed Description:
The objective of PRIISM is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients with acute ischemic stroke. Safety will be assessed by the device-related serious event rate as it compares to other similar therapies. The events include but are not limited to symptomatic hemorrhage, vessel dissection, embolization and overall morbidity and mortality. Target vessels include the basilar, internal carotid and middle cerebral (M1 and M2 segments) arteries.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Trial to Evaluate the MindFrame System in the Recanalization of Occluded Vessels in Patients Experiencing an Ischemic Stroke
Study Start Date : March 2009
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ischemic Stroke

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment Arm Device: MindFrame System
Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
Other Names:
  • IRIIS System
  • Clot
  • Thrombus
  • Mechanical Thrombectomy
  • Ischemic Stroke
  • Intervention
  • Neurovascular


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and Within 30 Minutes of Placing the Guide Catheter. [ Time Frame: Immediately postprocedure ]

    TIMI Flow is a perfusion scoring system from 0-3 referring to levels of blood flow assessed during reperfusion procedures:

    TIMI 0 flow (no perfusion) TIMI 1 flow (penetration without perfusion) TIMI 2 flow (partial reperfusion) TIMI 3 flow (complete perfusion) is normal flow


  2. Procedural Success as Determined by the Overal Percentage of Patients Who Achieve TIMI Grade 2/3 Flow, With or Without the Use of Adjuvant Therapy, in All Treatable Vessels as Confirmed by the Final Post Treatment Angiogram. [ Time Frame: Immediately postprocedure ]

    TIMI Flow is a scoring system from 0-3 referring to levels of blood flow assessed during percutaneous coronary angioplasty:

    TIMI 0 flow (no perfusion) TIMI 1 flow (penetration without perfusion) TIMI 2 flow (partial reperfusion) TIMI 3 flow (complete perfusion) is normal flow


  3. Clinical Success [ Time Frame: 90 days postprocedure ]
    Clinical Success as determined by achievment of a Modified Rankin Scale score of 0-2 at 90 days postprocedure. The modified Rankin Scale is a measure of a patient's level of functional independence with 0=normal and 6-death. Patients with a score of 0-2 are considered functionally independent.


Secondary Outcome Measures :
  1. Number of Device-related Serious Adverse Events [ Time Frame: Treatment to 90 days postprocedure ]
    Evaluation of the safety of using the MindFrame System based on device-related serious adverse event(s). Device-related serious adverse events are defined as vessel perforation, intramural arterial dissection, device-related symptomatic intracranial hemorrhage, and significant embolization in a previously uninvolved arterial territory.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. NIHSS 6 to 30 within 6 hours of symptom onset
  2. Pre-stroke Modified Rankin Score ≤ 2
  3. Large Vessel Occlusion
  4. Patient/patient guardian is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluation.

  5. Patients must meet at least one of the following criteria:

    • Eligible for Intravenous rt-PA
    • Eligible for Intra-arterial rt-PA - IA rt-PA initiated within 6 hours of symptom onset
    • Patient presents within 6 hours of symptom onset

Exclusion Criteria:

  1. Pregnancy
  2. Glucose <50mg/dL
  3. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR>3.0
  4. Patient received heparin within 48 hours with a PTT greater than 2 times the lab normal.
  5. Patient has baseline platelets < 30,000
  6. Evidence of rapidly improving neurological signs of stroke at time of enrollment
  7. Coma
  8. Pre-existing neurological or psychiatric disease that could confound the study results
  9. Known severe allergy to contrast media or nitinol
  10. Patient has severe sustained hypertension
  11. CT/MRI scan reveals significant mass effect with midline shift
  12. Patient's angiogram shows an arterial stenosis >50% proximal to the embolus.
  13. Patient's anticipated life expectancy is less than 3 months
  14. Participation in another clinical investigation that could confound the evaluation of the study device
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00810095


Locations
Layout table for location information
Germany
University of Heidelberg
Heidelberg, Germany
Sponsors and Collaborators
MindFrame, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Martin Bendszus, MD, PhD Heidelberg University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: MindFrame, Inc.
ClinicalTrials.gov Identifier: NCT00810095    
Other Study ID Numbers: EU-PRIISM-01
First Posted: December 17, 2008    Key Record Dates
Results First Posted: July 26, 2012
Last Update Posted: July 26, 2012
Last Verified: June 2012
Keywords provided by MindFrame, Inc.:
Cerebral Infarction
Stroke
Vascular Diseases
Central Nervous System Diseases
Penumbra
 Functional Outcome
Aphasia
Hemiplegia
Left sided weakness
Right Sided weakness
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Ischemic Stroke
Cerebral Infarction
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Infarction
Necrosis